![]() ![]() With this approval, Abbott continues to advance its Infinity DBS system to provide personalized and patient-centric innovations for people with movement disorders. Food and Drug Administration (FDA) for Infinity Deep Brain Stimulation (DBS) system to target an area of the brain called the internal globus pallidus. In January 2020, Abbott received approval from the U.S. The Leading Players in the Global Personalized Medicine Market :Ībbott Laboratories, Agilent Technologies, Amgen, Astellas Pharma, Astrazeneca, Bayer AG, Celgene Corporation, Glaxosmithkline Plc, Illumina, Johnson & Johnson, Laboratory Corporation, Merck, Novartis AG, Roche Holding AG, Siemens AG, Takeda Pharmaceutical Company Limited, and Others. This research report has been accumulated based on static and dynamic views of the businesses.Ĭlick Here to Get a Free Sample PDF Copy of the Latest Research on the Personalized Medicine Market 2023 Before Purchase: This report study describes the projected growth of the global market for approaching years from 2023 to 2029. This Personalized Medicine Market research report pinpoints the competitive landscape of industries to understand the competition at the International level. This report studies top players in the global market and divides the Market into several parameters. The global Personalized Medicine market research report published by market insight reports discovers the current outlook in global and key regions from the viewpoint of Major Players, Countries, Product Types, and end industries. The global Personalized Medicine market was valued at US$ 2.15 trillion in 2022 and is expected to reach over US$ 5.7 trillion by 2030, poised to grow at a notable CAGR of 11.8% from 2023 to 2029.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |